tbuckley/cabot-search huggingface dataset:
Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations
Authors: Christian Menzer, Alexander M. Menzies, Matteo S. Carlino, Irene Reijers, Emma J. Groen, Thomas Eigentler, Jan Willem B. de Groot, Astrid A.M. van der Veldt, Douglas B. Johnson, Frank Meiss, Max Schlaak, Bastian Schilling, Hans M. Westgeest, Ralf Gutzmer, Claudia Pföhler, Friedegund Meier, Lisa Zimmer, Karijn P.M. Suijkerbuijk, Thomas Haalck, Kai-Martin Thoms, Karin Herbschleb, Jonas Leichsenring, Alexander Menzer, Annette Kopp-Schneider, Georgina V. Long, Richard Kefford, Alexander Enk, Christian U. Blank, Jessica C. Hassel
Journal: Journal of Clinical Oncology (2019)

PURPOSE BRAF/MEK inhibition is a standard of care for patients with BRAF V600E/K–mutated metastatic melanoma. For patients with less frequent BRAF mutations, however, efficacy data are limited. METHODS In the current study, 103 patients with metastatic melanoma with rare, activating non-V600E/K BRAF mutations that were treated with either a BRAF inhibitor (BRAFi), MEK inhibitor (MEKi), or the combination were included. BRAF mutation, patient and disease characteristics, response, and survival data were analyzed. RESULTS Fifty-eight patient tumors (56%) harbored a non-E/K V600 mutation, 38 (37%) a non-V600 mutation, and seven had both V600E and a rare BRAF mutation (7%). The most frequent mutations were V600R (43%; 44 of 103), L597P/Q/R/S (15%; 15 of 103), and K601E (11%; 11 of 103). Most patients had stage IV disease and 42% had elevated lactate dehydrogenase at BRAFi/MEKi initiation. Most patients received combined BRAFi/MEKi (58%) or BRAFi monotherapy (37%). Of the 58 patients with V600 mutations, overall response rate to BRAFi monotherapy and combination BRAFi/MEKi was 27% (six of 22) and 56% (20 of 36), respectively, whereas median progression-free survival (PFS) was 3.7 months and 8.0 months, respectively ( P = .002). Of the 38 patients with non-V600 mutations, overall response rate was 0% (zero of 15) to BRAFi, 40% (two of five) to MEKi, and 28% (five of 18) to combination treatment, with a median PFS of 1.8 months versus 3.7 months versus 3.3 months, respectively. Multivariable analyses revealed superior survival (PFS and overall survival) with combination over monotherapy in rare V600 and non-V600 mutated melanoma. CONCLUSION Patients with rare BRAF mutations can respond to targeted therapy, however, efficacy seems to be lower compared with V600E mutated melanoma. Combination BRAFi/MEKi seems to be the best regimen for both V600 and non-V600 mutations. Yet interpretation should be done with care because of the heterogeneity of patients with small sample sizes for some of the reported mutations.
Evolution of myeloid-derived suppressor cells and objective response rate in relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) patients after receiving immunotherapy
Authors: C Jiménez Cortegana, N Palazón Carrión, E Nogales Fernández, M A Nieto García, V Sánchez Margalet, M D C Álamo de la Gala, M Suengas Martínez de Ilárduya, E Montilla Burgos, I Araújo Fernández, F Henao Carrasco, A Martín García-Sancho, F. Carnicero, E Rios Herranz, F. de la Cruz Vicente, R. Fernández, A Rueda Dominguez, L. de la Cruz Merino
Journal: Annals of Oncology (2019)
Prognostic role of RLF/MYCL1 and circPVT1 in SCLC
Authors: C.T. Storlazzi, V. Longo, S. Tommasi, D. Tolomeo, D. Traversa, G. Visci, A. Lonoce, G. Macchia, A. Labbate, P. D’addabbo, P. Pizzutilo, L. Muscarella, D. Petriella, R. Lacalamita, F.A. Zito, M.A. Botticella, A.M. Catino, D. Galetta
Journal: Annals of Oncology (2019)
Noninferiority on overall survival of every-2-weeks vs weekly schedule of cetuximab for first-line treatment of RAS wild-type metastatic colorectal cancer
Authors: S. Kasper, A.-L. Cheng, F. Overkamp, M. Rouyer, C. Foch, F.-X. Lamy, R. Esser, D. Messinger, V. Rothe, W. Chen, T. Brodowicz, C.C. Zielinski
Journal: Annals of Oncology (2019)
Safety of high doses of somatostatin analogs in well differentiated NENs in elderly
Authors: M. Cani, L. Incorvaia, D. Fanale, I. De Luca, F. Gelsomino, T. Ibrahim, S. Pusceddu, F. Riccardi, S. Tafuto, G. Lamberti, A. Faggiano, A. La salvia, M. Albertelli, S. Massironi, M. Rinzivillo, G. butturini, V. Bazan, D. Campana, A. Russo, G. Badalamenti
Journal: Annals of Oncology (2019)
Evaluation of microsatellite instability testing through cell-free DNA sequencing
Authors: S. Zhang, J.S. LoCoco, A. Mentzer, B.M. Crain, S. Katz, G. Berry, Y. Fu, T. Jiang, C. Zhao, S. Bilke, T. Pawlowski, K. Kruglyak
Journal: Annals of Oncology (2019)
Real life use of talimogene laherparepvec in melanoma in centers in Austria and Switzerland
Authors: C. Hoeller, J.M. Ressler, M. Karasek, V Aedo Lopez, L. Koch, H. Kehrer, P. Koelblinger, F. Weihsengruber, J. Kofler, E. Richtig, O.A. Michielin, C. Hafner
Journal: Annals of Oncology (2019)
Tumour mutation burden and microsatellite instability in colorectal cancer
Authors: F. Fenizia, R. Esposito Abate, R. Pasquale, C. Roma, M. Lambiase, N. Chicchinelli, P. Graziano, G. Botti, F. Tatangelo, G. Scognamiglio, F. Pietrantonio, N. Normanno
Journal: Annals of Oncology (2019)
Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecules APVO436 and APVO437 Have Broad Activity Against Primary Human AML Cells In Vitro
Authors: Colin D. Godwin, Olivia M. Bates, George S. Laszlo, Rebecca Gottschalk, Michael R. Comeau, Gabriela H. Hoyos, Roland B. Walter
Journal: Blood (2017)
Avelumab-cetuximab-radiotherapy versus standards of care (SoC) in patients (pts) with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Safety phase of randomized trial GORTEC 2017-01 (REACH)
Authors: Y. Tao, A. Auperin, X. Sun, C. Sire, L. Martin, A. Coutte, C. Lafond, J. Miroir, X. Liem, F. Rolland, A. Maillard, N. Colin-Barailhou, C. Michel, J. Thariat, J. Guigay, J. Bourhis
Journal: Annals of Oncology (2019)
The immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: Clinical significance for pathological response and survival
Authors: E.F. Nassif, B. Mlecnik, C. Thibault, X. Barthere, M. Auvray, D. Bruni, E. Comperat, A. Colau, F. Hermitte, P. Camparo, P. Colin, D. Bruno, M. Bennamoun, F. Audenet, A. Mejean, V. Verkarre, R. Zakopoulou, A. Bamias, S. Oudard, J. Galon
Journal: Annals of Oncology (2019)
Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab (BEV), carboplatin (C) and paclitaxel (P) for advanced cervical cancer (aCC)
Authors: A. Redondo, N. Colombo, L.M. Dreosti, M. McCormack, A Nogueira Rodrigues, G. Scambia, A. Roszak, M. Donica, B. Ulker, A González Martín
Journal: Annals of Oncology (2019)
Expression of immune response biomarkers in head and neck squamous cell carcinoma (HNSCC) in irradiated area
Authors: C. Pflumio, J. Thomas, J. Salleron, J.-C. Faivre, C. Borel, G. Dolivet, X. Sastre-Garau, L. Geoffrois
Journal: Annals of Oncology (2019)
Emergence of ESR1 mutation in cell-free DNA during first line aromatase inhibitor and palbociclib: An exploratory analysis of the PADA-1 trial
Authors: F.-C. Bidard, C. Callens, B. Pistilli, F. Dalenc, T. de La Motte Rouge, R. Sabatier, J.-S. Frenel, S. Ladoire, C. Dubot, J.-M. Ferrero, F. Clatot, D. Nierges, S. Everhard, J. Lemonnier, I. Bieche, A. Pradines, J.-Y. Pierga, F. Berger, T. Bachelot, S. Delaloge
Journal: Annals of Oncology (2019)
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Authors: M.D.M. Noblejas López, C. Nieto-Jiménez, E.M. Galán-Moya, M. Burgos, J.C. Montero, M. Gómez-Juárez, A. Pandiella, A. Ocaña
Journal: Annals of Oncology (2019)
Modulation of Hemolytic and Hemoglobin/Heme Scavenging Profiles in Sickle Cell Anemia, Hereditary Spherocytosis and Paroxysmal Nocturnal Hemoglobinuria
Authors: Fernanda F.C. Fabris, Flavia C. Leonardo, Rodolfo Cancado, Rafaela Mendonça, Angelica A. Silveira, Kleber Yotsumoto Fertrin, Sara Teresinha Olalla Saad, Fernando F. Costa, Nicola Conran, Camila B. Almeida
Journal: Blood (2016)
Impact of somatic PIK3CA and ERBB family mutations on pathological complete reponse (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Authors: Sinead Toomey, Alex J Eustace, Joanna Fay, Malgorzata Milewska, Ausra Teiserkiene, Elaine Kay, Darran O'Connor, Leonie S Young, Norma O'Donovan, William Grogan, Oscar S. Breathnach, Janice Maria Walshe, M. John Kennedy, Arnold D. Hill, Colm Power, Deirdre Duke, Niamh Hambly, William M. Gallagher, John Crown, Bryan Hennessy
Journal: Journal of Clinical Oncology (2016)

591 Background: TCGA analysis revealed that somatic EGFR, ERBB2, ERBB3 and ERBB4 mutations (ERBB family mutations) occur alone or co-occur with somatic PIK3CA mutations in 19% of HER2-positive breast cancers. As ERBB family mutations can activate the AKT pathway it is likely that they have similar canonical signalling effects to PI3K pathway mutations. Therefore we have investigated their combined impact on response to neoadjuvant HER2-targeted therapies. Methods: Baseline breast tumour biopsies were available from 83 patients with HER2-positive early breast cancer who were enrolled to the phase 2 TCHL neoadjuvant study assessing TCH (docetaxel, carboplatin, trastuzumab) versus TCHL (TCH and Lapatinib), each for 6 cycles. We used mass spectrometry-based genotyping to determine the frequency and outcome implications of 105 ERBB family and PIK3CA single nucleotide mutations. Results: PIK3CA mutations were detected in 19 patient tumour samples (22.9%), while EGFR and ERBB3 mutations were each detected in 3 samples (3.6%). ERBB4 mutations were detected in 4 samples (4.8%). EGFR, ERBB3 and ERBB4 mutations co-occurred with PIK3CA mutations in one sample each. Mutation frequency was similar in each treatment arm (29.7% in TCH arm and 34.6% in TCHL arm), and was not influenced by ER status (29.6% in ER-negative patients, 31.8% in ER-positive patients) or PR status (30.8% in PR-negative patients, 31.3% in PR-positive patients). We analysed the correlation between tumour PIK3CA/ERBB family mutation status and pathological complete response (pCR), and found no significant difference in pCR rates between patients with wild-type (WT) tumours and patients whose tumours carried mutations (38.7% vs 54.5%, respectively; p = 0.312). However, in the TCHL (but not the TCH) group the pCR rate was higher for patients with PIK3CA/ERBB family mutated tumours than for patients with WT tumours (58.3% vs 14.3%; 95% CI, 1.038 to 16.6%; p = 0.0375). Conclusions: Our results indicate that patients who receive neoadjuvant TCHL and have PIK3CA/ERBB family mutated tumours are more likely to have a pCR relative to patients with WT tumours.
VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)
Authors: R.L. Coleman, G.F. Fleming, M.F. Brady, E. Swisher, K.D. Steffensen, M. Friedlander, A. Okamoto, K. Moore, N. Ben-Baruch, T.L. Werner, A. Oaknin, J.-H. Nam, C.A. Leath, S. Nicum, D. Cella, D.M. Sullivan, P.J. Ansell, M. Dinh, C. Aghajanian, M.A. Bookman
Journal: Annals of Oncology (2019)
Comparison of immuno-oncology (IO) biomarkers in adenocarcinoma (ACB), urothelial carcinoma (UCB) and squamous cell carcinoma (SCCB) of the bladder, with interim results from PURE01
Authors: D. Raggi, J.S. Ross, S.M. Ali, J. Chung, A.B. Schrock, R. Madison, B.M. Alexander, P. Grivas, A. Necchi
Journal: Annals of Oncology (2019)
Immune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients
Authors: M. Saint-Ghislain, L. Geoffrois, L. Gastaud, T. Lesimple, S. Negrier, N. Penel, J.-E. Kurtz, Y. Le Corre, S. Gardrat, R. Barnhill, N. Cassoux, P. Mariani, V. Servois, S. Piperno-Neumann, M. Rodrigues
Journal: Annals of Oncology (2019)
Abstract 13637: Outcome and Freedom From Re-Intervention After Systemic Atrioventricular Valve Intervention in Functional Single Ventricle Patients: A Case-Control Study
Authors: Richard U Garcia, Mahsun Yuerek, David J Goldberg, Andrew C Glatz, Heather Griffis, J. William Gaynor, Jack Rychik
Journal: Circulation (2017)

Introduction: A competent systemic atrioventricular valve (SAVV) in patients with functional single ventricle heart disease is thought to be an important determinant of long-term outcome. We aim to...
APACHE: An open label, randomized, phase II study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with refractory germ cell tumours (GCT): Results from the expanded combination therapy cohort
Authors: E. Farè, D. Raggi, P. Giannatempo, M. Colecchia, G. Calareso, S.M. Ali, J. Chung, J.S. Ross, A. Necchi
Journal: Annals of Oncology (2019)
Abstract 16198: Modifying Heparan Suflate Glycoasminoglycan Content and Chemokine Binding in Transplanted Donor Organs Improves Vascular Inflammation and Rejection
Authors: Sriram Ambadapadi, Hao Chen, Meeyong Bartee, Donghang Zheng, Sufi Morshed, Dara Wakefield, William Clapp, Alexandra Lucas
Journal: Circulation (2015)

Background: Transplant allograft vasculopathy (TAV) is the leading cause for late transplant organ loss. TAV is induced by activation and invasion of inflammatory monocytes and T cells in response to chemokine binding to glycosaminolycans (GAGs) in the endothelial glycocalyx. We investigated the effect of inhibiting heparin sulfate (HS-GAG) / chemokine interactions on rejection in a renal transplant model with (a) heparin sulfate HS-GAG deficient (Ndst1 -/- ) donor mice and (b) a virus-derived chemokine modulating protein M-T7, that is blocks C, CC and CXC interaction with GAGs. Methods: BALB/c renal allograft recipients receiving either Ndst1 -/- (C57BL/6 background) or C57Bl/6 wild type (WT) donor kidneys (n = 48 each) were treated for 10 days with either Saline, M-T7 or one of three M-T7 point mutations (100 ng/gm) with differing inhibitory actions for HS-GAG / chemokine interaction. No other immunosuppressants were added. Results: Ndst1 -/- kidneys had 10X reduced HS content and markedly reduced sulfation compared to WT kidneys. Overall acute rejection and vasculitis scores were significantly reduced in Ndst1 -/- donor kidneys (P &lt; 0.0001). In WT donors, M-T7 significantly reduced rejection and vasculitis (P &lt; 0.0001), but interestingly, lost activity in Ndst1 -/- allografts. CD3+ cells were significantly reduced (P &lt; 0.0001) in Ndst1 -/- donor grafts and with M-T7 treatment in WT transplants and TH17+ cells were significantly reduced in spleen cell isolates. M-T7 point mutation E 209 I retained activity in both Ndst1 -/- and WT donors while but R 171 E was active only in WT. The third mutant F 137 D was inactive. PCR array analysis detected significant decreases in IL-4, NOS2 and CC chemokine 20, in Ndst1 -/- donor transplants or in WT transplants with M-T7 or M-T7 mutant treatments with significant reductions in TAV. Conclusions: A critical role played by HS-GAG / chemokine interactions in the DONOR allograft transplant is demonstrated by these studies. Significant decreases in acute rejection and inflammatory vasculitis are seen in Ndst1 -/- donors with saline treatment and after treatment of C57Bl/6 WT donor grafts with M-T7. HS-GAG composition of donor organs has a potential decisive effect on transplant viability.
NUP98-KDM5A Fusion Gene Is Not Exclusive to Acute Megakaryoblastic Leukemia and Is an Independent Predictor of Poor Prognosis
Authors: Sanne Noort, Robert B Gerbing, Todd A Alonzo, Jenny L. Smith, Edwin Sonneveld, Franco Locatelli, Dirk Reinhardt, Andre Baruchel, Jan Stary, Marry M. Van den Heuvel-Eibrink, C. Michel Zwaan, Soheil Meshinchi
Journal: Blood (2017)
Thermal monitoring during photothermia: hybrid probes for simultaneous plasmonic heating and near-infrared optical nanothermometry
Authors: Marta Quintanilla, Isabel García, Irene de Lázaro, Rafaela García-Alvarez, Malou Henriksen-Lacey, Sandra Vranic, Kostas Kostarelos, Luis M. Liz-Marzán
Journal: Theranostics (2019)

The control of temperature during photothermal therapy is key to preventing unwanted damage in surrounding tissue or post-treatment inflammatory responses.Lack of accurate thermal control is indeed one of the main limitations that hyperthermia techniques present to allow their translation into therapeutic applications.We developed a nanoprobe that allows controlled local heating, combined with in situ nanothermometry.The design of the probe follows a practical rationale that aims at simplifying experimental requirements and exploits exclusively optical wavelengths matching the first and second biological windows in the near-infrared.Methods: Hybrid nanostructures were chemically synthesized, and combine gold nanostars (photothermal agents) with CaF2:Nd 3+ ,Y 3+ nanoparticles (luminescent nanothermometers).Both components were simultaneously excited in the near-infrared range, at 808 nm.Following the goal of simplifying the thermal monitoring technique, the luminescent signal was recorded with a portable near-infrared detector.The performance of the probes was tested in 3D tumor spheroids from a human glioblastoma (U87MG) cell line.The location of the beads within the spheroids was determined measuring Nd 3+ emission in a commercial Lightsheet microscope, modified in-house to be able to select the required near-infrared wavelengths.The temperature achieved inside the tumor spheroids was deduced from the luminescence of Nd 3+ , following a protocol that we developed to provide reliable thermal readings.Results: The choice of materials was shown to work as an optically excited hybrid probe.Depending on the illumination parameters, temperature can be controlled in a range between 37 ºC and 100 ºC.The near-infrared emission of nanothermometers also allows microscopic tracking of the hybrid nanostructures, confirming that the probes can penetrate deeper into the spheroid mass.We observed that, application of optical thermometry in biological environments requires often neglected considerations, since the optical signal changes along the optical path.Accordingly, we developed data analysis protocols that guarantee reliable thermal readings.Conclusions: The prepared hybrid probes are internalized in 3D tumor spheroids and can be used to induce cell death through photothermal effects, while simultaneously measuring the local temperature in situ.We show that luminescent thermometry in biomedical applications requires the development of protocols that guarantee accurate readings.Regarding photothermal treatments, we observe a sharp thermal threshold at around 55 ºC (for 10 min treatments) that separates high survival ratio from complete cell death.
Correlation of thyroglobulin (Tg) oscillations with progression-free survival (PFS) in patients with radioactive iodine-refractory (RAI-R) differentiated thyroid carcinoma (DTC) treated with multikinase inhibitors (MKI)
Authors: J. Hernando Cubero, A. García Álvarez, M. Roca Herrera, D. Acosta, M. Diez, R. Ferrer, A. Garcia Burillo, C. Zafon, C. Iglesias, J. Capdevila
Journal: Annals of Oncology (2019)
Comprehensive pan-cancer analysis of somatic mutations in drug transporters to reveal acquired and intrinsic drug resistance in 3149 metastatic cancer patients
Authors: S. Bins, W.S. van de Geer, J. van Riet, N. Steeghs, H.M.W. Verheul, C. van Herpen, P.O. Witteveen, V.C.G. Tjan-Heijnen, M.P. Lolkema, E.E. Voest, S. Sleijfer, E. Cuppen, H.J.G. van de Werken, R.H.J. Mathijssen
Journal: Annals of Oncology (2019)
SUNitinib with EVOfosfamide (TH-302) for G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) naïve for systemic treatment. The SUNEVO phase II trial of the Spanish task force group for neuroendocrine and endocrine tumours (GETNE)
Authors: E. Grande, C. Lopez, T. Alonso Gordoa, M. Benavent, J. Capdevila, A. Teulé, A. Custodio, I. Sevilla, P. Gajate, J. Molina-Cerrillo, J. Hernando Cubero, R. Garcia-Carbonero
Journal: Annals of Oncology (2019)
Gene therapy for hereditary hearing loss by SLC26A4 mutations in mice reveals distinct functional roles of pendrin in normal hearing
Authors: Min-A Kim, Sung Huhn Kim, Nari Ryu, Ji-Hyun Ma, Ye-Ri Kim, Jinsei Jung, Chuan-Jen Hsu, Jae Young Choi, Kyu-Yup Lee, Philine Wangemann, Jinwoong Bok, Un-Kyung Kim
Journal: Theranostics (2019)

Rationale: Mutations of SLC26A4 that abrogate pendrin, expressed in endolymphatic sac, cochlea and vestibule, are known to cause autosomal recessive sensorineural hearing loss with enlargement of the membranous labyrinth.This is the first study to demonstrate the feasibility of gene therapy for pendrin-related hearing loss.Methods: We used a recombinant viral vector to transfect Slc26a4 cDNA into embryonic day 12.5 otocysts of pendrin-deficient knock-out (Slc26a4 ∆/∆ ) and pendrin-deficient knock-in (Slc26a4 tm1Dontuh/tm1Dontuh ) mice.Results: Local gene-delivery resulted in spatially and temporally limited pendrin expression, prevented enlargement, failed to restore vestibular function, but succeeded in the restoration of hearing.Restored hearing phenotypes included normal hearing as well as sudden, fluctuating, and progressive hearing loss. Conclusion:Our study illustrates the feasibility of gene therapy for pendrin-related hearing loss, suggests differences in the requirement of pendrin between the cochlea and the vestibular labyrinth, and documents that insufficient pendrin expression during late embryonal and early postnatal development of the inner ear can cause sudden, fluctuating and progressive hearing loss without obligatory enlargement of the membranous labyrinth.
Distinct Hypothalamic Neurons Mediate Estrogenic Effects on Energy Homeostasis and Reproduction
Authors: Yong Xu, Thekkethil P. Nedungadi, Liangru Zhu, Nasim Sobhani, Boman G. Irani, Kathryn E. Davis, Xiaorui Zhang, Fang Zou, Lana M. Gent, Lisa D. Hahner, Sohaib A. Khan, Carol F. Elias, Joel K. Elmquist, Deborah J. Clegg
Journal: Cell Metabolism (2019)
Prognostic factors in metastatic seminomatous germ cell tumours and elevated human chorionic gonadotrophin (HCG): A study of the G3
Authors: C. Seidel, G. Daugaard, T. Nestler, A. Tryakin, C.D. Fankhauser, T. Hermanns, J. Aparicio, J. Heinzelbecker, P. Pfaffenholz, U. De Giorgi, R. Cathomas, A. Lorch, A. Fingerhut, F. Gayer, F. Bremmer, P. Giannatempo, A. Necchi, G. Aurilio, C. Oing, C. Bokemeyer
Journal: Annals of Oncology (2019)
Bintrafusp alfa (M7824) and eribulin mesylate in treating patients with metastatic triple negative breast cancer (TNBC)(NCT03579472)
Authors: J.K. Litton, S. Damodaran, I.I. Wistuba, F. Yang, A. Contreras, A. Tam, L. Ojalvo, I. Dussault, C. Helwig, S. Moulder
Journal: Annals of Oncology (2019)
Outcome of Children with All Given HSCT from Unrelated Volunteers Has Significantly Improved over Time and Now Is Comparable to That of Children Transplanted from an HLA-Identical Sibling.
Authors: Franco Locatelli, Marco Zecca, Andrea Pession, Cornelio Uderzo, Giorgio Dini, Franca Fagioli, Claudio Favre, Valentino Conter, Roberto Rondelli, Federico Bonetti, Chiara Messina
Journal: Blood (2004)
Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407
Authors: S.F. Powell, D Rodriguez Abreu, C.J. Langer, A. Tafreshi, L. Paz-Ares, H.-G. Kopp, J. Rodríguez-Cid, D. Kowalski, Y. Cheng, T. Kurata, M.M. Awad, J. Lin, B. Zhao, M.C. Pietanza, B. Piperdi, M.C. Garassino
Journal: Annals of Oncology (2019)
Abstract 10784: Major Life Events Prior to Hospitalization for Acute Myocardial Infarction are Associated with Worse Outcomes at 1 Year
Authors: Erica C Leifheit-Limson, Yan Li, Kimberly J Reid, Stanislav V Kasl, Judith H Lichtman
Journal: Circulation (2011)

Background: Major adverse life events are associated with increased risk of acute myocardial infarction (AMI), but little is known about whether these life events influence post-AMI outcomes during...